The Employees' State Insurance Corporation (ESIC) on June 13, 2026, issued notification on Testing of Medicines under MoU between ITL & ESIC.
The document pertains to the testing of various medicines in accordance with the MoU signed between M/s ITL and ESIC dated July 15, 2025. It provides details of multiple drug samples collected on June 2, 2026, including their batch numbers, manufacturers, dates of manufacture and expiry, and applicable rate contracts (RC/CPSE).
The medicines covered include formulations such as Esomeprazole 40 mg, Amitriptyline (10 mg and 25 mg), Thiocolchicoside 4 mg, Vildagliptin with Metformin, Mupirocin ointment, Metformin 500 mg, Levofloxacin 500 mg, and nasal drops containing Sodium Chloride and other preservatives. These drugs have been manufactured by various pharmaceutical companies including Chemipharma Pvt. Ltd., Biodeal Pharmaceuticals Ltd., Unicure India Ltd., Ultra Drugs Pvt. Ltd., and Karnataka Antibiotics & Pharmaceuticals Ltd.
Each drug sample has been assigned a testing rate (generally ₹2,200 per sample, with one instance of ₹1,800), and all samples were collected for testing on June 2, 2026. The document ensures compliance with quality testing requirements under the agreed framework between ITL and ESIC.
The total testing charges amount to ₹21,600, excluding GST, which will be levied additionally as applicable.
[File No.: U-16012/69/2025-Med.Store]
